A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a ...

A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated strong response rates ...

Several antibody–drug conjugates (ADCs), using ... containing immunochemotherapy regimens in relapsed/refractory B-cell lymphoma and leukemia. Other ADCs directed against other B-cell lineage ...

LUND, SE / ACCESS Newswire / March 21, 2025 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class ...

Takeda's Adcetris has become the first drug recommended for routine NHS use as a treatment for previously untreated ...

Geoffrey Shouse, DO, PhD, discusses the growing interest in bispecific antibodies within the field of oncology. Geoffrey Shouse, DO, PhD, an assistant professor at City of Hope Comprehensive Cancer ...